![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biomagnetics Diagnostics Corp (CE) | USOTC:BMGP | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP - News) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, Cholera and malaria detection, and other innovative technologies, today announced CEO Clayton Hardman attended a series of meetings on the important topic of diagnosing and managing tuberculosis (“TB”) with industry leaders from the Centers for Disease Control, the Foundation for New Innovative Diagnostics (“FIND”), the World Health Organization and the University of KwaZulu-Natal, South Africa and others, at a Symposium hosted by Los Alamos National Laboratory.
While at the Global Tuberculosis Surveillance Workshop held this month in Santa Fe, New Mexico, Biomagnetics Diagnostics Corp. met with the engineering team from Los Alamos that built the bench-top prototype unit of its Integrated Optical Biosensor (“IOBS”) for the detection of TB. As a result of these meetings, development of the “IOBS” moved forward as the engineers at Los Alamos agreed to meet with Lathrop Engineering to fabricate a production model and miniaturization unit of the IOBS. With the assistance of LANL the Company also made arrangements to collaborate with other leaders in the field to conduct validation studies on the IOBS device and TB assay upon finalization, and assist with developing the HIV assay, and assist with clinical trials and approvals.
Additionally, Mr. Hardman is planning to attend further meetings where he expects to gain insights into the current status of tuberculosis related activities, interests and goals at the Center for Disease Control (“CDC”), one of the premier U.S. organizations for the study and containment of prevalent global diseases.
Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. commented, “Attending the Global Tuberculosis Surveillance Workshop sponsored by LANL has been a valuable experience. We are glad to have been a part of this symposium and look forward to working with the alliances to bring the IOBS unit to market.”
About Biomagnetics Diagnostics Corp.
Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company and an acquirer of other innovative technologies. The Company is currently developing a waveguide-based advanced integrated optical biosensor through its cooperative research and development agreement with Los Alamos National Security, LLC, which will initially be used for cholera, tuberculosis, HIV and malaria diagnosis. More information on Biomagnetics Diagnostics Corp. can be seen at www.biomagneticsbmgp.com.
1 Year Biomagnetics Diagnostics (CE) Chart |
1 Month Biomagnetics Diagnostics (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions